Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and
zoledronic acid with zoledronic acid alone to see how well they work when given after
radiation therapy in treating patients with solitary plasmacytoma of bone. Ixazomib citrate
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Lenalidomide may help the immune system kill abnormal blood cells or cancer cells.
Dexamethasone is a drug used in chemotherapy that may cause tumor cells to die. Zoledronic
acid may prevent bone fractures and reduce bone pain, and may also improve survival. Standard
treatment for this cancer is radiation therapy alone. It is not yet known whether ixazomib
citrate, lenalidomide, dexamethasone and zoledronic acid or zoledronic acid alone is more
effective, and whether adding these treatments after radiation therapy is more effective than
radiation therapy alone in treating patients with solitary plasmacytoma of bone.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.